GC Biopharma Corp.: all 78 studies

Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Phase 2/3 Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or OlderNot yet recruitingNCT07883928Phase 2/3
• A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 YearsRecruitingNCT07054099Phase 3
• A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy AdultsRecruitingNCT06997627Phase 1/2
• A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry DiseaseRecruitingNCT06858397Phase 1/2
• A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.RecruitingNCT05686759Phase 3
• Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella VaccinationRecruitingNCT05422508Phase 2
• Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral ImmunodeficiencyCompletedNCT02783482Phase 3Results posted
• A Phase 1 Study to Evaluate the Safety and Immunogenicity of GC4006A in Healthy AdultsActive, not recruitingNCT07728396Phase 1
• An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta)CompletedNCT07344376Phase 3
• Evaluation of the Effectiveness and Safety of Rozetel Tablet in Patients After PCI: A Multi-Center Observational StudyActive, not recruitingNCT07084246
• Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)Active, not recruitingNCT06567769Phase 1
• A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fed ConditionsStatus unknownNCT05729386Phase 1
• A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fasting ConditionsStatus unknownNCT05703984Phase 1
• An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 YearsStatus unknownNCT05664152Not applicable
• A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia PatientCompletedNCT05493631Phase 1
• A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS ⅡActive, not recruitingNCT05422482Phase 1
• Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral ImmunodeficiencyActive, not recruitingNCT04565015Phase 3
• COVIDIG (COVID-19 Hyper-ImmunoGlobulin)CompletedNCT04555148Phase 2
• A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy AdultsStatus unknownNCT04238975Phase 2
• Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:CompletedNCT04175522Phase 2
• Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki DiseaseCompletedNCT04003844Phase 4
• A Study of GC3107(BCG Vaccine) in Healthy InfantsCompletedNCT03947138Phase 3
• A Study of GC1111 in Hunter Syndrom PatientsCompletedNCT03920540Phase 3
• A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia PatientsCompletedNCT03855696Phase 1
• A Study of GC1102(Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B PatientsStatus unknownNCT03801798Phase 2
• A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy SubjectsCompletedNCT03657719Phase 2
• HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102Status unknownNCT03519113Phase 2/3
• Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral ImmunodeficiencyWithdrawnNCT03492710Phase 3
• A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination ChemotherapyCompletedNCT03454620Phase 1/2
• A Study of MG1111 in Healthy ChildrenCompletedNCT03375502Phase 2/3
• Study to Investigate the Safety and Efficacy of GC3107 (BCG Vaccine) in Healthy AdultsStatus unknownNCT03363178Phase 1
• A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy AdultsCompletedNCT03357263Phase 1
• A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of AgeStatus unknownNCT03285997Phase 3
• A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Subjects Aged 65 Years and OlderCompletedNCT02917304Phase 3
• A Study to Evaluate Efficacy and Safety of GC3110B in Healthy AdultsStatus unknownNCT02915809Phase 3
• Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) VaccineStatus unknownNCT02813486Phase 1/2
• Study of Idursulfase-beta (GC1111) in Hunter SyndromeStatus unknownNCT02663024Phase 2
• A Multicenter, Double-blind, Parallel, Non-inferiority, Phase III StudyStatus unknownNCT02658409Phase 3
• A Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B PatientsCompletedNCT02569372Phase 1
• Study to Evaluate the Immunogenicity and Safety of Hantavax in Healthy AdultStatus unknownNCT02553837Phase 3
• A Study to Evaluate the Efficacy and Safety of 'GC3110A(QIV)' in Healthy ChildrenCompletedNCT02541253Phase 3
• Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy AdultsCompletedNCT02367638Phase 1
• To Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy AdultsCompletedNCT02361866Phase 3
• Study to Evalutate Long-term Immunity of Hantavax in High Risk Population of HFRSCompletedNCT02360514Phase 3
• Phase II Study to Evaluate the Efficacy and Safety of GC6101A in Subjects With GastritisStatus unknownNCT02353039Phase 2
• A Multicenter, Double-blind, Parallel Phase III StudyCompletedNCT02352584Phase 3
• Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid CancerStatus unknownNCT02352571Phase 1
• A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant RecipientsCompletedNCT02304315Phase 2
• Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)CompletedNCT02249221Phase 1/2
• A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine)CompletedNCT02121782Phase 1/2
• Demonstrate the Lot-to-lot Consistency of 3 Consecutive Batches and to Evaluate the Efficacy and Safety of GC FLU®Pre-filled Syringe Injection and 'GC FLU®Injection' Administration.CompletedNCT02067117Phase 4
• A Prospective Observational Study on Discontinuation of Medication of Shinbaro CapsuleStatus unknownNCT02064634
• An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune ThrombocytopeniaCompletedNCT02063789Phase 3
• The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) PatientsStatus unknownNCT02044692
• Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia AStatus unknownNCT02027779Phase 3
• Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult VolunteersCompletedNCT01987011Phase 3
• A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy VolunteersCompletedNCT01954238Phase 1
• Safety Study of MG1102 in Patients With Solid TumorsTerminatedNCT01809912Phase 1
• To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC3102C' Administered Intramuscularly in Healthy AdultsCompletedNCT01750814Phase 3
• Study for Hyalobarrier to Evaluate Anti-adhesive Effect and Safety Compared to Guardix-SG After ThyroidectomyCompletedNCT01696305Phase 3
• Evaluate the Safety and Exploratory Efficacy of GC1119CompletedNCT01653444Phase 1
• A Study to Assess Safety, Tolerability, and Pharmacokinetics of Orally Administered GCC4401C in Healthy VolunteersCompletedNCT01651234Phase 1
• Safety and Efficacy of HunteraseCompletedNCT01645189Phase 3
• A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109CompletedNCT01624532Phase 2
• Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia AStatus unknownNCT01619046Phase 3
• Safety and Pharmacokinetics Study of Healthy Male Adults When Repeatedly Administered Through Intravenous InjectionCompletedNCT01606163Phase 1
• To Evaluate the Safety of 'Shinbaro Capsule'in Patients With OsteoarthritisCompletedNCT01604239Phase 4
• Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia ACompletedNCT01568580Phase 3
• Efficacy and Safety of Shinbaro CapsuleCompletedNCT01535417Phase 3
• Study of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki DiseaseCompletedNCT01524939Phase 4
• Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary ImmunodeficiencyCompletedNCT01406470Phase 3
• To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy ChildrenCompletedNCT01402713Phase 2/3
• Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult VolunteersCompletedNCT01389466Phase 1/2
• To Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of ErythropoietinCompletedNCT01363934Phase 1
• GCPGC in Chemotherapy-induced NeutropeniaCompletedNCT01328938Phase 2/3
• GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic ShockTerminatedNCT01315496Phase 3
• To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome PatientsCompletedNCT01301898Phase 1/2
• A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) VaccineCompletedNCT01201902Phase 3

← GC Biopharma Corp. overview and focus areas